Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 ASX Growth Companies With Up To 23% Insider Ownership

In This Article:

As the Australian market navigates a period of slower trade and investor caution amid ongoing global tensions, identifying growth companies with significant insider ownership can offer valuable insights into potential investment opportunities. In this environment, where confidence is tempered by geopolitical uncertainties, stocks with strong insider commitment may signal a higher level of trust in the company's long-term prospects.

Top 10 Growth Companies With High Insider Ownership In Australia

Name

Insider Ownership

Earnings Growth

Alfabs Australia (ASX:AAL)

10.8%

41.3%

Fenix Resources (ASX:FEX)

21.1%

47.8%

Cyclopharm (ASX:CYC)

11.3%

97.8%

Acrux (ASX:ACR)

15.5%

106.9%

Newfield Resources (ASX:NWF)

31.5%

72.1%

Echo IQ (ASX:EIQ)

19.8%

111.1%

Titomic (ASX:TTT)

11.2%

77.2%

Plenti Group (ASX:PLT)

12.7%

85%

Image Resources (ASX:IMA)

16.1%

127.3%

BETR Entertainment (ASX:BBT)

38.6%

77.5%

Click here to see the full list of 93 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

Aurelia Metals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Aurelia Metals Limited is an Australian company involved in the exploration and production of mineral properties, with a market capitalization of A$456.99 million.

Operations: The company's revenue is primarily derived from its operations at the Peak Mine (A$245.13 million), Dargues Mine (A$73.90 million), and Hera Mine (A$5.98 million).

Insider Ownership: 23.9%

Aurelia Metals shows promise as a growth company with substantial insider ownership, evidenced by significant insider buying in recent months. The company has returned to profitability, reporting A$17.95 million net income for the half-year ending December 2024 compared to a loss previously. While gold and silver production declined, copper output increased significantly. Analysts forecast robust annual earnings growth of 23.6%, outpacing the broader Australian market's expected growth rate of 11.7%.

ASX:AMI Earnings and Revenue Growth as at Apr 2025
ASX:AMI Earnings and Revenue Growth as at Apr 2025

Clarity Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★☆

Overview: Clarity Pharmaceuticals Ltd is a clinical stage radiopharmaceutical company focused on research and development of radiopharmaceutical products in Australia and the United States, with a market cap of A$539.87 million.

Operations: The company's revenue segment consists of Radiopharmaceutical Development, generating A$10.78 million.